Metraipolis › archive › dc_c23b48cccda5

Cost-utility analysis of stratified isoniazid dosing by NAT2 genotype compared with isoniazid standard regimen for new patients with pulmonary tuberculosis in… — Europe PMC PMID:41971281

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41971281
DOI
10.3389/fpubh.2026.1772312
License (as archived)
solo-consultazione
Archived
2026-11-03T19:36:16.635Z
SHA-256 of the archived text
e0f5fa22b49239c57a8d7e51a9418995dd975e0b5287a389f78e5af5d12ad28a
Stable URL of this page
https://metraipolis.com/documento/dc_c23b48cccda5

How to cite

Cost-utility analysis of stratified isoniazid dosing by NAT2 genotype compared with isoniazid standard regimen for new patients with pulmonary tuberculosis in… — Europe PMC PMID:41971281 — Europe PMC (en), https://europepmc.org/article/MED/41971281 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_c23b48cccda5 (Metraipolis archive dc_c23b48cccda5, sha256 e0f5fa22b49239c57a8d7e51a9418995dd975e0b5287a389f78e5af5d12ad28a)
BibTeX
@misc{dcc23b48cccda5,
  title = {Cost-utility analysis of stratified isoniazid dosing by NAT2 genotype compared with isoniazid standard regimen for new patients with pulmonary tuberculosis in… — Europe PMC PMID:41971281},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41971281},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_c23b48cccda5; sha256 e0f5fa22b49239c57a8d7e51a9418995dd975e0b5287a389f78e5af5d12ad28a},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41971281. Agents can read the archived copy with the MCP tool read_document.